Ligand Pharmaceuticals (LGND) has completed its approximately US$739 million cash acquisition of XOMA Royalty Corporation, adding seven commercial products and more than 100 development and commercial stage assets to its royalty portfolio of more than 200 assets.
See our latest analysis for Ligand Pharmaceuticals.
Ligand Pharmaceuticals’ latest move comes after a strong run in the stock, with the share price up 55.84% year to date and supported by a 128.54% 1 year total shareholder return. Recent 7 day and 1 day share price declines contrast with a 16.98% 30 day and 32.71% 90 day share price return. This suggests momentum has cooled slightly in the very near term while remaining firm over a longer window as investors react to the expanded royalty portfolio and new credit facility.
If Ligand Pharmaceuticals’ royalty model interests you, it may be worth widening your watchlist to include other healthcare and biotech companies using AI technologies through our screener for 40 healthcare AI stocks.
Ligand Pharmaceuticals now trades below both analyst targets and an internal fair value estimate, even after the XOMA deal and new credit facility. Is that discount a cushion for caution, or a signal the market sees real risk?
Most Popular Narrative: 40% Undervalued
The most followed narrative values Ligand Pharmaceuticals at $297.50 per share, close to the recent $296.26 price, yet still frames the stock as materially undervalued based on long term cash flow potential.
Strong revenue and earnings growth are expected as Ligand broadens its high margin royalty portfolio, with multiple partnered drugs (such as O2vir, Filspari, Qarziba, and Zelsuvmi) in various stages of commercialization or late stage development. This expanding royalty base enhances recurring revenue, earnings visibility, and long term cash flow predictability.
Curious what keeps that cash flow story working in the model? The narrative leans on faster revenue compounding, still high margins, and a future earnings multiple that assumes investors keep paying up for this royalty profile.
Result: Fair Value of $297.50 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, that cash flow narrative for Ligand Pharmaceuticals still depends on a concentrated set of royalty assets and on drug pricing trends that could pressure long term returns.
Find out about the key risks to this Ligand Pharmaceuticals narrative.
Another View on Ligand Pharmaceuticals’ Valuation
The SWS DCF model values Ligand Pharmaceuticals at $404.09 per share, compared with the $297.50 narrative fair value and the recent $296.26 price. This comparison points to a deeper undervaluation based on long term cash flows. If both are “right” in their own way, which set of assumptions do you trust more?
Look into how the SWS DCF model arrives at its fair value.
Next Steps
Uncertain whether the mixed signals around Ligand Pharmaceuticals point to opportunity or risk? Move quickly, review the full picture, and weigh the 3 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Ligand Pharmaceuticals?
If Ligand Pharmaceuticals has caught your attention, do not stop there. Use this moment to scan broader opportunities and stress test your portfolio with fresh ideas.
- Target steadier compounding by reviewing companies with proven fundamentals and strong finances through the solid balance sheet and fundamentals stocks screener (48 results).
- Hunt for potential value opportunities by checking companies that appear mispriced relative to their quality in the 47 high quality undervalued stocks.
- Prioritize resilience and sleep better at night by focusing on companies flagged for lower overall risk in the 78 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com